Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-17

Clinical Trial Update: Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating amrubicin as first-line chemotherapy for metastatic or unresectable soft tissue sarcoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amrubicin (amrubicin)

Snippet

Sponsor: University of Utah | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-17